McCollum Christoferson Group LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 0.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,938 shares of the life sciences company’s stock after selling 112 shares during the quarter. Illumina makes up approximately 3.0% of McCollum Christoferson Group LLC’s holdings, making the stock its 2nd biggest holding. McCollum Christoferson Group LLC’s holdings in Illumina were worth $8,059,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of ILMN. Massmutual Trust Co. FSB ADV boosted its stake in Illumina by 83.0% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 39 shares during the last quarter. Sapphire Star Partners LP bought a new position in Illumina in the fourth quarter valued at approximately $360,000. Financial Enhancement Group LLC bought a new position in Illumina in the third quarter valued at approximately $400,000. Machina Capital S.A.S. bought a new position in Illumina in the fourth quarter valued at approximately $1,099,000. Finally, Boston Family Office LLC lifted its stake in Illumina by 13.1% in the fourth quarter. Boston Family Office LLC now owns 4,620 shares of the life sciences company’s stock valued at $1,386,000 after buying an additional 535 shares in the last quarter. 90.46% of the stock is currently owned by institutional investors.

A number of research analysts have weighed in on the stock. OTR Global lowered shares of Illumina to a “positive” rating in a research note on Tuesday, April 2nd. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Wednesday, March 27th. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and lifted their price target for the company from $340.00 to $370.00 in a research note on Thursday, January 3rd. BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a research note on Tuesday, January 29th. Finally, Leerink Swann raised shares of Illumina to an “outperform” rating and cut their price target for the company from $380.00 to $365.00 in a research note on Wednesday, January 30th. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $346.97.

In related news, SVP Charles Dadswell sold 124 shares of the business’s stock in a transaction on Friday, February 1st. The shares were sold at an average price of $280.11, for a total transaction of $34,733.64. Following the transaction, the senior vice president now directly owns 6,879 shares in the company, valued at $1,926,876.69. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Omead Ostadan sold 1,260 shares of the business’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $294.62, for a total transaction of $371,221.20. Following the transaction, the senior vice president now owns 29,534 shares in the company, valued at $8,701,307.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,526 shares of company stock worth $9,558,427. 0.54% of the stock is owned by corporate insiders.

Shares of NASDAQ ILMN traded up $3.66 during midday trading on Thursday, reaching $328.52. The company’s stock had a trading volume of 888,878 shares, compared to its average volume of 948,518. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 0.23. Illumina, Inc. has a fifty-two week low of $226.62 and a fifty-two week high of $372.61. The company has a market capitalization of $47.75 billion, a PE ratio of 57.43, a price-to-earnings-growth ratio of 2.26 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.04). Illumina had a net margin of 24.79% and a return on equity of 24.51%. The business had revenue of $867.00 million during the quarter, compared to analyst estimates of $865.33 million. During the same quarter last year, the business earned $1.44 earnings per share. Illumina’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, sell-side analysts expect that Illumina, Inc. will post 6.53 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/mccollum-christoferson-group-llc-has-8-06-million-stake-in-illumina-inc-ilmn/2955805.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Recommended Story: What does the Dow Jones Industrial Average (DJIA) measure?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.